CurrentAetnaPolicy 0157

Obesity Surgery

Defines medical necessity, exclusions, and coding for bariatric and obesity-related surgical procedures for Aetna members; affects providers requesting coverage for obesity surgery and related procedures.

Policy Summary

PayerAetna

PolicyObesity Surgery

Policy CodePolicy 0157

Change TypeNo material clinical or coverage changes

Effective Date

Next Review Date

Key ActionObtain prior authorization and document participation in an intensive multicomponent behavioral intervention (≥12 sessions) and prior conservative management when requesting coverage for bariatric procedures.

SourceLink

BMI ≥ 40adult BMI threshold

BMI ≥ 35 + comorbidityalternate eligibility

12+behavioral sessions

10%initial weight-loss goal

Medical Necessity and Coverage Rules

inv-01: Initial bariatric surgery medical necessity — RYGB, LASGB, sleeve gastrectomy, BPD/DS, SADI-S, SIPS

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial bariatric surgery (RYGB, LASGB, sleeve gastrectomy, BPD/DS, SADI‑S, SIPS) is considered medically necessary when ALL of the following selection criteria are met:

ALL of the following

Member is an adult (age ≥ 18 years) or an adolescent who has completed skeletal growth (generally ≥13 years for girls, ≥15 years for boys).
Persistent severe obesity documented in contemporaneous clinical records, defined as either: BMI > 40 kg/m2 (or > 37.5 kg/m2 for persons of Asian ancestry), OR BMI > 35 kg/m2 (or > 32.5 kg/m2 for persons of Asian ancestry) with at least one of the following severe comorbidities: clinically significant obstructive sleep apnea, coronary heart disease with objective documentation, medically refractory hypertension (BP >140/90 mmHg despite ≥3 antihypertensive agents of different classes), type 2 diabetes mellitus, or nonalcoholic steatohepatitis (NASH) confirmed by biopsy or advanced fibrosis by noninvasive testing.
Member has attempted weight loss previously without successful long-term weight reduction and has participated in an intensive multicomponent behavioral intervention documented in the medical record (program with ≥12 sessions on separate dates within 2 years prior to surgery; may be group or individual, in-person or remote, and includes nutrition, physical activity, and behavioral modification components).
Screening for obstructive sleep apnea using a validated tool (e.g., ESS, STOP, STOP‑Bang, Berlin, Wisconsin Sleep Questionnaire, MVAP). Documentation that screening was performed must be in the medical record (screening not required if member already has a diagnosis of OSA).
For members with active substance abuse disorder, history of eating disorder (in addition to obesity), or severe psychiatric disturbance (schizophrenia, borderline personality disorder, suicidal ideation, uncontrolled severe depression) or who are currently under care of a psychologist/psychiatrist, preoperative psychological clearance by a licensed psychologist or psychiatrist is required to confirm ability to provide informed consent and comply with pre/post-operative regimen.

inv-02: Vertical banded gastroplasty (VBG) — Covered when ALL criteria are met

Vertical banded gastroplasty (VBG) is considered medically necessary only when ALL of the following are met:

ALL of the following

Member meets the general selection criteria for obesity surgery (see Initial bariatric surgery criteria).
Member is at increased risk of adverse consequences from RYGB due to the presence of any of the following: demonstrated extensive intestinal adhesions from prior major abdominal surgery or trauma, hepatic cirrhosis with elevated liver function tests, inflammatory bowel disease (Crohn's disease or ulcerative colitis), poorly controlled systemic disease (ASA Class IV), or radiation enteritis.

inv-03: Management of bariatric surgery complications — medically necessary items listed

Management of bariatric surgery complications — the following interventions are considered medically necessary:

ANY of the following

Removal of a gastric band when recommended by the treating physician (e.g., band erosion, infection, irreparable malfunction).
Surgery to correct complications from bariatric surgery such as obstruction, stricture, erosion, or band slippage when clinically indicated and documented.
Surgery for symptomatic 'candy cane' (Roux) syndrome when diagnosis is confirmed by endoscopy or upper GI contrast studies and member has compatible symptoms (abdominal pain, nausea, emesis).
Replacement of an adjustable band when there are complications (e.g., port leakage, irreparable slippage) that cannot be corrected with band manipulation or adjustments.
Conversion of sleeve gastrectomy to Roux‑en‑Y gastric bypass for treatment of symptomatic gastroesophageal reflux disease (GERD) only when: (1) reflux is documented by abnormal 24‑hour pH monitoring or endoscopically proven esophagitis performed after sleeve gastrectomy; and (2) symptoms persist despite optimal medical therapy including behavioral modification and at least one month of maximum PPI therapy.
Repeat bariatric surgery (conversion or revision) for members whose initial bariatric surgery was medically necessary and who meet specified criteria, including inadequate success (sustained loss of >50% excess body weight at ≥2 years post‑procedure with documented compliance), revision for anatomic failures (e.g., dilated pouch or dilated gastrojejunal stoma) when primary procedure was initially successful and member has been compliant with prescribed nutrition and exercise program, or conversion from an adjustable band to sleeve, RYGB, or BPD/DS for complications not correctable with band manipulation/adjustment/replacement.

inv-04: Experimental and investigational procedures — list of not covered procedures and devices

The following procedures, devices, and techniques are considered experimental and investigational (not covered) due to insufficient evidence of safety or effectiveness:

ANY of the following

Adjunctive omentectomy performed solely to improve metabolic outcomes.
AspireAssist aspiration therapy except where FDA‑approved indications apply and criteria met; 'Band over bypass' (placement of LASGB over prior RYGB) and 'band over sleeve' (LASGB over sleeve gastrectomy).
Bariatric surgery performed solely to treat idiopathic intracranial hypertension or infertility in persons not meeting standard medical necessity criteria for obesity surgery.
Bariatric surgery for treatment of type 2 diabetes in persons with BMI < 35 kg/m2 (except when meeting updated specialty guidelines and payer‑specific diabetes surgery criteria if present).
Conversion of sleeve gastrectomy to Roux‑en‑Y gastric bypass for treatment of bile reflux, and conversion to sleeve gastrectomy for hypoglycemia post‑RYGB.
Duodenal‑jejunal bypass liners and endoscopic gastrointestinal bypass devices (e.g., EndoBarrier, ValenTx), NOTES techniques for bariatric surgery (including TORe, ROSE as primary NOTES bariatric procedures), intragastric balloons (except FDA‑cleared devices when used per indication), mini‑sleeve gastrectomy, laparoscopic gastric plication (LGCP), restorative obesity surgery endoluminal (ROSE), transoral gastroplasty, use of endoscopic closure devices (OTSC, OverStitch, StomaphyX) as primary NOTES bariatric procedures, and other novel devices or procedures lacking sufficient peer‑reviewed evidence.
Open adjustable gastric banding in contexts not meeting established criteria, prophylactic mesh placement for prevention of incisional hernia after open bariatric surgery, prophylactic pyloroplasty via botulinum toxin injection following LSG, vagus nerve blocking (VBLOC/Maestro) outside FDA‑cleared indications, loop gastric bypass and mini‑gastric bypass due to safety concerns and limited evidence, and Silastic ring vertical gastric bypass (Fobi pouch).
Measurement of serum C‑reactive protein as a routine predictor for complications following bariatric surgery (insufficient evidence to support routine use).

inv-05: Related routine procedures — routine procedures related to bariatric surgery

Related routine procedures associated with bariatric surgery:

ANY of the following

Routine cholecystectomy performed in concert with elective bariatric procedures is considered medically necessary given high incidence of gallbladder disease after bariatric surgery.
Routine liver biopsy during bariatric surgery is considered not medically necessary in the absence of signs or symptoms of liver disease (e.g., elevated liver enzymes, hepatomegaly, imaging suggesting cirrhosis). Biopsy may be indicated selectively for suspected cirrhosis or when noninvasive testing suggests advanced fibrosis/NASH.

inv-06: Surgical candidacy and preoperative requirements — Covered when ALL of the following are met

Surgical candidacy and preoperative requirements — candidate meets coverage when ALL of the following are met:

ALL of the following

Meets BMI and comorbidity thresholds as described in initial bariatric surgery criteria (BMI criteria, comorbidity documentation).
Documentation of prior attempts at non‑surgical weight loss and participation in an intensive multicomponent behavioral intervention (program documentation, ≥12 sessions within 2 years, or program records substituting for medical records).
Preoperative evaluation including screening for OSA (or documented diagnosis), appropriate medical clearance, and assessment for perioperative risk (ASA classification).
Preoperative nutritional assessment and plan, including assessment for micronutrient deficiencies and counseling by registered dietitian when indicated; plan for lifelong supplementation and follow‑up as appropriate.
For adolescents, criteria include completion of skeletal growth, failure of organized weight‑loss attempts (generally ≥6 months), severe obesity (BMI ≥40) with severe comorbidity or super‑obesity (BMI ≥50) with less severe comorbidity, referral to multidisciplinary pediatric bariatric team, and performance at centers able to collect long‑term outcomes data.

inv-07: Adolescent candidate criteria (expert panel) — adolescent and pediatric recommendations

Adolescent candidate recommendations (expert panel) —

ALL of the following

Bariatric surgery may be considered for adolescents who have completed bone growth (typically ≥13 years for girls and ≥15 years for boys).
Candidates should have severe obesity (BMI ≥40) with severe comorbidities or super‑obesity (BMI ≥50) with comorbidities that may be remedied by weight loss, and should have failed organized weight‑loss attempts (generally ≥6 months).
Referral should be to centers with multidisciplinary pediatric/adolescent weight management teams experienced in the unique needs of adolescents, with capacity to collect long‑term outcomes and provide comprehensive perioperative and long‑term follow‑up.

inv-08: Preoperative documentation and psychological evaluation — requirements for evaluation

Preoperative documentation and psychological evaluation requirements:

ALL of the following

Medical records must document the patient's participation and compliance with an intensive multicomponent behavioral intervention (program name, dates, attendance, progress). Program records from recognized commercial programs (e.g., Weight Watchers, Jenny Craig, OptiFast) may substitute when available.
Physician documentation of preoperative assessment, prescribed interventions, and progress toward weight‑loss goals (including counseling on diet, physical activity, and behavioral strategies).
Comprehensive psychological evaluation by a licensed psychologist or psychiatrist is required for candidates with history of severe psychiatric disturbance, active substance abuse, or other psychosocial factors that may impair informed consent or postoperative compliance.

inv-09: Liver biopsy / NAFLD considerations — liver assessment for bariatric candidates

Liver assessment and biopsy considerations for bariatric candidates:

ANY of the following

Routine liver biopsy at the time of bariatric surgery is not medically necessary in the absence of clinical or laboratory signs of liver disease. Selective biopsy may be indicated when suspected cirrhosis, unexplained hepatic abnormalities, or noninvasive testing (FibroScan, FibroTest/ActiTest, MRE, ELF) suggests advanced fibrosis or NASH.
Noninvasive tests (FIB‑4, NAFLD Fibrosis Score, transient elastography [FibroScan], magnetic resonance elastography) can be used as first‑line tools to identify advanced fibrosis; TE and MRE are useful at referral centers to select patients for biopsy.

inv-10: Procedure efficacy and safety summaries — procedure-specific summaries and comparative effectiveness/safety notes

Procedure‑specific efficacy and safety summaries — evidence and professional positions:

ANY of the following

RYGB: Considered the procedure of choice in many settings due to durable weight loss and comorbidity resolution; long‑limb RYGB may be used for super‑obese patients. Associated risks include nutritional deficiencies (iron, B12, calcium) and potential for anastomotic complications; laparoscopic approach has lower mortality and faster recovery but differing complication profiles compared with open surgery.
Sleeve gastrectomy: Increasingly used; evidence shows substantial short‑ to mid‑term weight loss. Considered an approved bariatric procedure by ASMBS though long‑term data are limited. May be used as first‑stage procedure for high‑risk/super‑obese patients; conversion to RYGB is a treatment option for refractory GERD when criteria are met.
LASGB (adjustable gastric band): Minimally invasive and adjustable, but associated with lower long‑term weight loss than RYGB and high reoperation/band‑removal rates; may be appropriate in selected patients and for salvage after prior RYGB in select circumstances but carries substantial revision risk.
Biliopancreatic diversion / Duodenal switch (BPD/DS): Produces greatest weight loss but with higher risk of long‑term nutritional deficiencies and requires lifelong follow‑up; may be considered for super‑obese patients in experienced centers.
Mini/loop gastric bypass and single‑anastomosis (e.g., mini gastric bypass, OAGB): Evidence limited and safety concerns (bile reflux) exist; regarded as investigational or requiring caution in adoption by some guidelines.
Endoscopic bariatric therapies (IGB, ESG, AspireAssist, TORe, endoscopic suturing, EndoBarrier, OverStitch, StomaphyX): Some FDA‑cleared devices (certain IGBs, AspireAssist) exist with short‑term efficacy; overall long‑term durability and comparative effectiveness vs surgical procedures remain limited. TORe and endoscopic revision techniques may reduce weight regain after RYGB in the short term but require further long‑term evidence and are often considered investigational when used as primary NOTES bariatric procedures.

inv-11: Sleeve gastrectomy: evidence and professional position

Sleeve gastrectomy — evidence summary and professional position:

ANY of the following

Systematic reviews and some randomized and observational studies show sleeve gastrectomy produces substantial short‑term weight loss and comorbidity improvements; evidence suggests greater weight loss than LASGB and similar short‑term weight loss compared with RYGB in limited trials, but long‑term comparative data are limited.
ASMBS considers sleeve gastrectomy an approved bariatric procedure, particularly useful as a first‑stage operation in high‑risk or super‑obese patients; professional organizations emphasize need for long‑term outcome data and monitoring for complications such as leaks, strictures, and reflux.

inv-12: Loop and mini gastric bypass — evidence and safety concerns

Loop and mini gastric bypass — evidence and safety concerns:

ANY of the following

Loop/mini gastric bypass procedures have limited high‑quality evidence (primarily case series) and raise concerns about bile reflux and marginal ulceration; many surgeons favor Roux‑en‑Y modifications to reduce reflux risk. These techniques are generally considered investigational or used with caution pending robust comparative trials.

inv-13: Laparoscopic adjustable gastric banding (LASGB) — evidence and outcomes

Laparoscopic adjustable gastric banding (LASGB) — evidence and outcomes:

ANY of the following

LASGB has documented sustained weight loss in many patients but generally less than RYGB and with higher rates of reoperation and device‑related complications (slippage, erosion, need for replacement). CMS and other assessments have supported LASGB in selected patients but long‑term revision rates should be considered.

inv-14: Intragastric balloon (IGB) — efficacy and safety

Intragastric balloon (IGB) — efficacy and safety summary:

ANY of the following

Randomized trials show IGBs can increase short‑term weight loss versus diet alone, but weight regain commonly occurs after removal; FDA has approved specific IGB systems with limited indications and recommended removal at specified durations (typically 6 months). Serious adverse events including rare deaths have been reported and safety surveillance continues.
Systematic reviews indicate moderate improvements in metabolic parameters with IGBs but limited long‑term durability and potential for serious adverse events (gastric perforation, obstruction).

inv-15: StomaphyX (endoluminal plication) — evidence

StomaphyX (endoluminal plication) — evidence:

ANY of the following

Limited evidence from small case series and one prematurely terminated randomized trial indicates StomaphyX did not meet predefined efficacy endpoints for revisional therapy; current evidence is insufficient to support routine use.

inv-16: Bariatric surgery and fertility/pregnancy — professional guidance

Bariatric surgery and fertility/pregnancy — guidance:

ANY of the following

Professional guidance (ACOG) states bariatric surgery should not be considered as a treatment for infertility. Pregnancy after bariatric surgery requires appropriate counseling and timing considerations to optimize maternal and fetal outcomes.

inv-17: Bariatric surgery for idiopathic intracranial hypertension — evidence

Bariatric surgery for idiopathic intracranial hypertension (IIH) — evidence:

ANY of the following

Case series and small observational studies suggest improvement or resolution of IIH symptoms and papilledema after bariatric surgery in many patients, but evidence is limited (Class IV) and prospective controlled studies are needed before surgery is recommended solely for IIH outside established obesity criteria.

inv-18: Evidence summaries — evidence and outcomes described

Evidence summaries and selected clinical trial context:

ANY of the following

Randomized trials and observational studies demonstrate bariatric surgery (RYGB, sleeve, BPD/DS) is superior to medical/lifestyle therapy for weight loss and type 2 diabetes remission in appropriately selected patients, including some lower‑BMI patients in metabolic surgery trials; however, long‑term 'hard' outcomes and durability in lower‑BMI populations require further study.
Systematic reviews indicate procedures that include malabsorptive components (BPD/DS) yield greater weight loss and diabetes remission but with higher nutritional risks; restrictive procedures yield less weight loss but fewer metabolic complications. Professional consensus statements (e.g., DSS‑II, ASMBS) have updated consideration of metabolic surgery thresholds for T2DM where evidence supports benefit in selected lower‑BMI patients, with ethnicity‑specific BMI adjustments (−2.5 kg/m2 for Asian patients).

inv-19: COVERAGE CRITERIA — surgery for T2DM guidance and BMI/control-based thresholds

Coverage guidance for surgery for type 2 diabetes mellitus (T2DM):

ALL of the following

Bariatric/metabolic surgery may be considered for treatment of T2DM in patients meeting established obesity surgery criteria (BMI ≥35 kg/m2 with inadequately controlled hyperglycemia) and, in selected cases, for patients with BMI 30.0–34.9 kg/m2 when hyperglycemia is inadequately controlled despite optimal medical therapy, consistent with international consensus statements and specialty guideline recommendations; ethnicity‑specific BMI adjustments apply (reduce thresholds by 2.5 kg/m2 for Asian patients).
Patient selection should consider glycemic control, duration of diabetes, comorbidity profile, and the risks/benefits of surgery with requirement for lifelong follow‑up and monitoring for nutritional deficiencies.

inv-20: Endoluminal revisions and suturing devices — evidence summary

Endoluminal revisions and suturing devices — evidence summary:

ANY of the following

Transoral outlet reduction (TORe) using endoscopic suturing devices has randomized sham‑controlled evidence showing modest but significant short‑term weight loss/stabilization after RYGB with dilated GJA; results are procedure‑ and device‑dependent and longer‑term durability is under investigation.
Endoscopic suturing and plication techniques (ESG, endoscopic sleeve gastroplasty, OverStitch, ROSE, StomaphyX) show promising early results in small studies/series but lack large randomized long‑term comparative data; some devices have limited or failed trials.

inv-21: Other procedures and devices — evidence summaries

Other procedures and devices — evidence summaries:

ANY of the following

VBLOC (vagal nerve blocking) has mixed trial results; FDA approved indications are narrow and evidence for broad use is insufficient. Endoscopic liners (EndoBarrier) showed short‑term weight loss but device complications and explantation limited adoption. AspireAssist has FDA approval for specific indications with demonstrated weight loss but requires careful patient selection due to contraindications and potential device‑related complications.

inv-22: Evidence summaries — clinical findings and trial context

Selected clinical findings and trial context for endoscopic and surgical innovations:

ANY of the following

Emerging procedures (ESG, endoscopic sleeve gastroplasty, SADI‑S, SIPS, mini procedures) show varied short‑term weight loss and comorbidity improvements in cohort studies and early trials; many societies recommend cautious adoption and collection of outcomes through registries and high‑quality trials to establish long‑term safety and effectiveness.

inv-23: Evidence summaries and device indications — study findings and FDA approvals

Device approvals and study summaries (selected):

ANY of the following

FDA approvals (e.g., ReShape Dual Balloon, Orbera, AspireAssist, Maestro VBLOC) do not alone constitute broad coverage; payer coverage decisions consider trial evidence, safety signals (including post‑market reports), indications, and clinical benefit versus alternatives.

inv-24: Coverage criteria for conversion of SG to RYGB — Covered when ALL of the following are met

Coverage for conversion of sleeve gastrectomy to RYGB specifically for GERD:

ALL of the following

Conversion of sleeve gastrectomy to Roux‑en‑Y gastric bypass is considered medically necessary for treatment of symptomatic GERD when: (1) reflux is documented by abnormal 24‑hour pH monitoring or endoscopically proven esophagitis performed after the sleeve gastrectomy; and (2) symptoms persist despite optimal medical therapy including behavioral modification and at least one month of maximum PPI therapy.
When performed primarily for treatment of reflux that meets these criteria, conversion is not considered repeat bariatric surgery for coverage purposes.

inv-25: Coverage stance for SILSG — Covered when ALL criteria met (single-incision procedures)

Single‑incision laparoscopic sleeve gastrectomy (SILSG) — coverage stance:

ANY of the following

SILSG is considered investigational/experimental when performed to achieve outcomes beyond those of conventional multi‑port laparoscopic sleeve gastrectomy due to limited evidence; available series suggest feasibility but RCTs are lacking to demonstrate superiority or equivalent safety in routine practice.

inv-26: Coverage stance for prophylactic mesh — statements re: prophylactic mesh placement

Prophylactic mesh placement for prevention of incisional hernia — stance:

ANY of the following

Routine prophylactic mesh placement at closure after open bariatric surgery is considered investigational due to insufficient high‑quality evidence; some meta‑analyses suggest reduced incisional hernia risk but further high‑quality studies (including laparoscopic contexts) and cost‑utility analyses are needed.

inv-27: Coverage considerations for SADI-S/SIPS/SADIS/SADS-p — coverage considerations

Coverage considerations for SADI‑S/SIPS/SADIS/SADS‑p:

ANY of the following

SADI‑S/SIPS and other single‑anastomosis duodeno‑ileal procedures are increasingly reported with promising weight loss and diabetes outcomes but long‑term data and standardized technique reporting are limited. These procedures may be considered in the context of clinical protocols or in experienced centers with registry reporting and long‑term follow‑up, and adoption should follow ASMBS guidance emphasizing cautious implementation and nutritional monitoring.

inv-28: Society position and evidence caveats — evidence and society recommendations

Society positions and evidence caveats:

ANY of the following

Professional societies (ASMBS, AACE, DSS‑II) provide evolving guidance recognizing metabolic benefits of bariatric procedures for T2DM and endorsing certain newer procedures with caution; they emphasize requirement for long‑term outcome data, registry reporting, and center expertise.

inv-29: Clinical evidence synthesis — summary of selected clinical evidence

Clinical evidence synthesis highlights:

ANY of the following

High‑quality randomized trials demonstrate superiority of bariatric/metabolic surgery over medical therapy for T2DM remission and glycemic control in selected patients; observational data support reductions in macrovascular events and durable weight loss for many procedures but comparative safety profiles and long‑term outcomes vary by procedure type.

inv-30: Background evidence summaries — evidence without explicit coverage rules in this segment

Background evidence summaries — selected narrative synthesis (no explicit coverage rules in this segment):

ANY of the following

The NIH Consensus (1998) and multidisciplinary task groups have informed candidate selection emphasizing prior medical therapy failure, documentation of BMI thresholds and comorbidities, and preoperative commitment to long‑term follow‑up. Intensive multicomponent behavioral interventions are recommended preoperatively (commonly ≥12 sessions) to assess commitment and promote pre‑surgical weight loss goals (eg, 5–10% or 10% as initial target).
Noninvasive testing for NAFLD/NASH (FIB‑4, NFS, transient elastography, MRE, serum biomarker panels) is useful to screen for advanced fibrosis; liver biopsy remains gold standard but is recommended selectively rather than routinely during bariatric surgery absent clinical indicators of liver disease.
Endoscopic bariatric therapies and revisional endoscopic procedures (TORe, ESG, OverStitch) are promising minimally invasive options for management of weight regain or as primary therapies in selected patients, but long‑term durability and comparative effectiveness versus surgical approaches remain under study; society guidance recommends registry reporting and further RCTs.
Emerging procedures (SADI‑S, SIPS, mini/one‑anastomosis procedures) show encouraging weight loss and metabolic outcomes in cohort series, but heterogeneity of techniques, variable follow‑up, and concerns about nutritional deficiencies warrant cautious adoption and further long‑term comparative research.

Prior Authorization, Documentation, and Operational Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for most bariatric procedures and endoscopic bariatric therapies. Check the member’s specific Aetna plan benefits before scheduling — some Aetna HMO/QPOS plans and some plans generally exclude surgical treatment of obesity. Prior authorization requests should state the procedure/device, indication, and applicable supporting documentation.

Prior authorization is required for bariatric operations and many endoscopic bariatric therapies.
Some Aetna plans exclude surgical treatment of obesity — confirm member benefits prior to authorization/submission.

Documentation Required

Procedure Codes and Coding Guidance

Include applicable procedure (CPT/HCPCS) and diagnosis (ICD-10) codes on authorization requests. Authorization review will reference the codes listed in the policy (examples include CPT 43644, 43848, 43236, 43253, 43290–43291 and relevant ICD-10 codes for BMI and GERD). Use the covered-code lists when selection criteria are met; otherwise, codes may be considered not covered or investigational.

Provide the CPT/HCPCS/ICD-10 codes relevant to the requested service.
Examples of procedure codes referenced: 43236, 43253, 43290, 43291, 43644, 43848, 43886.
Include ICD-10 codes documenting BMI and related diagnoses (eg, Z68.x, K21.x as applicable).

Prior Authorization

Behavioral Program Participation Required

Documentation of participation in an intensive multicomponent behavioral intervention is required prior to authorization for bariatric procedures. The program must be intensive (typically ≥12 sessions on separate dates) within 2 years prior to surgery (exceptions if final session within 2 years). Program records (eg, Weight Watchers, Jenny Craig, OptiFast) may substitute for medical records.

Document program name, dates of participation, number of sessions (≥12 recommended), components addressing nutrition, physical activity, and behavioral modification.
Program records can substitute for medical record documentation when available.
Behavioral program may be in-person or remote, group or individual.

Prior Authorization

Prior Authorization for Endoscopic Outlet Reduction (TORe)

For transoral outlet reduction (TORe) prior authorization should document indication (weight regain or inadequate loss after RYGB), evidence of a dilated gastrojejunostomy (GJA), prior conservative therapies (diet, behavioral, medications), and endoscopic measurements (GJA diameter, pouch size) when available. Authorization is recommended for repeat TORe or revisional endoscopic procedures and should include prior bariatric history and operator experience.

Indication: weight regain or inadequate weight loss after RYGB with dilated GJA (provide pre-procedure GJA diameter).
Document prior conservative management (dietary, behavioral, pharmacologic) and any prior TORe procedures.
Provide prior bariatric operative history, date(s) of index surgery, and operator/center experience with TORe or endoscopic revision.

Prior Authorization

Revisions and Novel Devices — Authorization Recommended

Prior authorization is recommended for bariatric revisions and novel or device-based therapies (eg, intragastric balloons, EndoBarrier, VBLOC, AspireAssist, ESG, SADI-S). Provide detailed justification: indication for revision, prior treatments attempted, device name, operator/center experience, and follow-up plan. Where evidence is limited, authorization may be denied or require additional documentation.

For revisional surgery provide indication (eg, GERD, leak, obstruction, inadequate weight loss), time since primary procedure, and prior conservative/endoscopic treatments.
For novel devices/procedures provide device name, FDA status, trial evidence, and operator/center experience.
Authorization requests for investigational/limited-evidence devices may require additional outcomes data or may be denied.

Prior Authorization

VBLOC Prior Authorization Considerations

VBLOC (vagal nerve blocking/Maestro) is FDA-approved for limited BMI ranges but the evidence base is insufficient. Prior authorization should document trial of supervised weight-management program within the required timeframe and include rationale for device use. Expect additional scrutiny or potential denial given limited evidence of long-term benefit.

VBLOC FDA indication: adults with BMI 40–45, or BMI 35–39.9 with related health condition and prior supervised weight-management attempt within 5 years.
Document prior supervised weight-management program; include program name and dates.
Evidence insufficiency may trigger request for further documentation or denial.

Prior Authorization

AspireAssist Prior Authorization

AspireAssist prior authorization should confirm device-specific indications and contraindications: age ≥22 years, BMI 35–55 kg/m2, and failure of non-surgical weight-loss therapy. Document excluded conditions (eg, bulimia, binge eating disorder, certain prior abdominal surgeries, pregnancy, inflammatory bowel disease, significant cardiopulmonary disease). Include plan for concurrent lifestyle counseling and follow-up.

Confirm patient meets FDA age/BMI criteria and has failed non-surgical weight-loss therapy.
Document contraindications (bulimia, binge eating disorder, pregnancy, IBD, certain prior abdominal surgery, uncontrolled hypertension, serious cardiopulmonary disease).
Describe planned supervised lifestyle counseling and follow-up schedule per trial/device protocol.

Prior Authorization

Authorization for SG to RYGB Conversion

Authorization for conversion of sleeve gastrectomy (SG) to Roux-en-Y gastric bypass (RYGB) should state the indication (eg, refractory GERD after SG or inadequate weight loss), documentation of prior anti-reflux medical therapy for GERD, diagnostic work-up (endoscopy, pH/manometry if performed), and prior conservative measures. Provide operative history and explain why conversion is clinically indicated.

Document failure of medical anti-reflux therapy prior to considering conversion for GERD.
Provide preoperative diagnostics (upper GI study, endoscopy, hiatal hernia assessment).
Include prior bariatric operative details and time since SG.

Prior Authorization

Center/Surgeon Experience and Follow-up Plans

For complex or novel procedures (eg, SADI-S/SIPS, revisional operations, advanced endoscopic therapies), prior authorization is likely to require documentation of center/surgeon/operator experience, planned follow-up, and data-reporting commitments. Centers with accreditation or evidence of high-volume experience strengthen authorization requests.

Provide center accreditation, surgeon/operator case volume, and evidence of multidisciplinary follow-up capability.
Describe post-operative follow-up plan including nutrition monitoring and registry reporting (eg, MBSAQIP) when requested.
Lack of documented expertise or follow-up plans may increase risk of denial.

Prior Authorization

Prior Authorization Justification for SADI-S/SIPS

Prior authorization for SADI-S/SIPS should include a clear justification: indication (primary vs conversion), prior management attempts, detailed operative plan (pouch/ sleeve size and common channel length), anticipated perioperative risk mitigation, and commitment to report outcomes to registries (eg, MBSAQIP). Limited long-term evidence may require additional documentation.

Document indication for SADI-S/SIPS (primary bariatric vs revisional) and prior therapeutic attempts.
Provide operative details (sleeve size, common channel length) and data-reporting plan to MBSAQIP/registries.
Expect requests for perioperative outcome data and diabetes remission metrics to justify approval.

Prior Authorization

Prior Authorization — TORe and Revisional Endoscopic Procedures

Prior authorization is recommended for TORe and other revisional endoscopic procedures. Required documentation includes indication, prior bariatric history, objective measures of a dilated GJA/pouch, prior conservative therapy, and operator experience. Repeat or staged endoscopic revisions should include rationale and prior procedure records.

Provide pre-procedure GJA and pouch measurements and evidence of failed conservative management.
Include prior bariatric operation details and previous endoscopic/surgical revision history.
Document endoscopist/operator experience and complication management plan.

Note

Endoscopic vs Surgical Revision — Prior Authorization Note

When choosing endoscopic versus surgical revision, be aware evidence suggests lower serious adverse event rates with endoscopic revision in selected patients. Prior authorization requests should describe why endoscopic approach is preferred and include operator expertise and prior outcomes data if available.

Document comparative rationale favoring endoscopic revision (lower SAE rates reported) and why surgical revision is not preferred.
Provide operator experience and center capability for managing complications of either approach.

Prior Authorization

Prior Authorization for Endoscopic Bariatric Therapies

For endoscopic bariatric therapies and novel devices, prior authorization should confirm indication, prior conservative therapies, device name and FDA status, operator experience, and plan for multidisciplinary care. Limited long‑term evidence may prompt denial or request for additional documentation.

Confirm device name, FDA approval status (if applicable), and patient eligibility per device labeling.
Document failure of comprehensive conservative therapy (diet, behavioral, pharmacotherapy) prior to device use.
Provide operator training/experience and program for multidisciplinary follow-up.

Prior Authorization

Evidence of Dilated GJA and Failed Conservative Therapy Required

Authorization requests for TORe should demonstrate objective evidence of a dilated GJA (eg, diameter measurements) and documentation that conservative therapies (dietary, behavioral, medical) have failed. Absence of such documentation may result in denial.

Provide pre-procedure GJA diameter and any imaging/endoscopic measurements.
Document prior conservative management attempts and duration.
Explain why TORe is clinically indicated versus additional conservative or surgical options.

Documentation Required

Psychological Evaluation Requirement

Psychological evaluation: candidates with severe psychiatric history, active substance abuse, uncontrolled depression, or other significant psychopathology should have a comprehensive preoperative psychologist/psychiatrist evaluation documented. Authorization may require this evaluation for patients with relevant psychiatric histories.

Document psychological/psychiatric assessment when history indicates significant psychopathology or current psychiatric care.
Include statements regarding suitability for surgery, capacity for informed consent, and plan for managing psychiatric conditions pre- and post-operatively.

Denial Risk

Denial Risk and Investigational/Safety Concerns

Certain procedures carry elevated denial risk or coverage limitations: open LASGB is noncovered for Medicare beneficiaries; intragastric balloons have reported deaths and serious AEs and may face increased scrutiny; investigational devices or those with insufficient evidence (eg, some endobarrier, novel NOTES techniques) may be denied.

Open LASGB may be non-covered for Medicare beneficiaries; verify plan-specific coverage.
Intragastric balloon systems have FDA safety communications and reported deaths — expect heightened scrutiny and documentation requirements.
Devices/procedures lacking long-term evidence (EndoBarrier, certain NOTES approaches) may be considered investigational and not covered.

Documentation Required

Medical Record Documentation Requirements

Medical record documentation expectations: include behavioral program records or medical record evidence of participation and compliance, baseline BMI measured prior to the preoperative preparatory program, comprehensive assessment and progress notes, psychiatric documentation when indicated, and device-specific contraindications. Lack of required documentation may result in denial of authorization.

Document baseline BMI measured prior to the preoperative behavioral program.
Include program participation records (dates, sessions attended, content) and clinician assessment of progress.
Provide psychological evaluation reports when indicated and document contraindications to devices (eg, AspireAssist, intragastric balloons).

Documentation Required

Device Implantation and Follow-up Documentation

Device implantation and follow-up documentation: for intragastric balloons, EndoBarrier, AspireAssist, ESG and similar interventions, include device model/name, implantation/removal dates, procedural details, complications, planned device- or procedure-specific follow-up, and management of device contraindications.

Document device name/model, date of implantation and planned removal (eg, 6 months for ReShape Dual Balloon).
Provide follow-up schedule, dietary/lifestyle program adherence plan, and monitoring for device-specific adverse events.
Record contraindications and any prior abdominal or bariatric surgeries that affect candidacy.

Documentation Required

ESG Procedural and Follow-up Documentation

ESG and other endoscopic sleeve procedures: include procedural details, post-procedure follow-up plan with multidisciplinary team, anticipated percent total body weight loss and monitoring for adverse events. Small-study evidence and shorter-term follow-up mean operator experience and center expertise are important in authorization decisions.

Provide number of sutures/technique used for ESG, anticipated follow-up visits, and multidisciplinary support (nutrition, behavioral health).
Document center and operator experience with ESG and prior outcomes when available.

Documentation Required

CPT, HCPCS and ICD-10 Codes

Covered CPT Codes (if selection criteria met)CPTCovered

43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (Roux Limb 150 cm or less).
43645	with gastric bypass and small intestine reconstruction to limit absorption [laparoscopic gastric diversion with gastro-jejunal reconstruction].
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components) [not covered if history of prior Roux-en-Y gastric bypass or sleeve gastrectomy] [not covered with gastric plication].
43771	Revision of adjustable gastric restrictive device component only.
43772	Removal of adjustable gastric restrictive device component only.
43773	Removal and replacement of adjustable gastric restrictive device component only.
43774	Removal of adjustable gastric restrictive device and subcutaneous port components.
43775	Longitudinal gastrectomy (ie, sleeve gastrectomy).
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty.
43843	Other than vertical-banded gastroplasty [not covered for transoral gastroplasty (TG), vertical sutured gastroplasty, endoluminal vertical gastroplasty, endoscopic sleeve gastroplasty] [not covered for open gastric banding].

1–10 of 18

1/2

Other related CPT codes / codes noted (some limited coverage or context-specific)CPT

0312T	Vagus nerve blocking therapy; laparoscopic implantation of neurostimulator electrode array.
0313T	Vagus nerve blocking therapy; laparoscopic revision or replacement of vagal trunk neurostimulator electrode array.
0317T	Vagus nerve blocking therapy; neurostimulator pulse generator electronic analysis, includes reprogramming when performed.
15876-15879	Suction assisted lipectomy; head and neck, trunk, upper/lower extremities.
43620	Gastrectomy, total; with esophagoenterostomy.
43621	With Roux-en-Y reconstruction.
43622	With formation of intestinal pouch, any type.
43631	Gastrectomy, partial, distal; with gastroduodenostomy.
43632	With gastrojejunostomy.
43633	With Roux-en-Y reconstruction.

1–10 of 12

1/2

HCPCS codes not covered for indications listedHCPCSNot Covered

0312T	Vagus nerve blocking therapy (morbid obesity) - listed as not covered for indications in CPB.
C9784	Gastric restrictive procedure, endoscopic sleeve gastroplasty - HCPCS not covered for indications listed in CPB.
C9785	Endoscopic outlet reduction - HCPCS not covered for indications listed in CPB.
J0585	Injection, onabotulinumtoxinA, 1 unit - HCPCS not covered for indications listed in CPB.

ICD-10 diagnosis codes covered if selection criteria are metICD-10Covered

E66.01	Morbid (severe) obesity due to excess calories.
E66.09	Obesity, unspecified.
E66.3	Overweight.
K75.81	Nonalcoholic steatohepatitis (NASH).
K91.1	Postgastric surgery syndromes [Roux syndrome].
Z68.41-Z68.45	Body mass index [BMI] 40 or greater, adult.
Z68.35-Z68.39	Body mass index [BMI] 35.0 - 39.9 or greater, adult.
Z68.32-Z68.34	Body mass index [BMI] 32.0-34.9, adult.
Z68.54	Body mass index [BMI] pediatric, greater than or equal to 95th percentile for age.
Z98.84	Bariatric surgery status.

ICD-10 codes not covered for indications listed in CPBICD-10Not Covered

E11.00-E11.9	Type II diabetes [not covered for persons with BMI less than 35].
G93.2	Benign intracranial hypertension [Idiopathic] (not covered for persons not meeting medical necessity criteria).
K21.00-K21.01	Gastro-esophageal reflux disease with esophagitis [for persons not meeting medical necessity criteria].

Endoscopic CPT/Category III codes referencedCPT

43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance
43253	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided transmural injection of diagnostic or therapeutic substance(s) or fiducial marker(s)
0813T	Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon
43290	Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon
43291	with removal of intragastric bariatric balloon(s)

Surgical CPT codes referencedCPT

43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (Roux Limb 150 cm or less)
43848	Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device (separate procedure)
43886	Gastric restrictive procedure, open; revision of subcutaneous port component only

ICD-10 diagnosis codes referencedICD-10

N46.01 - N46.9	Male infertility (listed for persons not meeting medical necessity criteria for obesity surgery)
N97.0 - N97.9	Female infertility (listed for persons not meeting medical necessity criteria for obesity surgery)
Z68.1 - Z68.31	Body Mass Index 0 – 31.9
Z98.890	Other specified postprocedural states (post anti-reflux surgery) (for persons not meeting medical necessity criteria for obesity surgery)
K30	Functional dyspepsia (listed among ICD-10 codes not covered for indications in CPB)
K59.8	Other specified functional intestinal disorders (dilated gastrojejunostomy)
K95.09	Other complications of gastric band procedure (dilated gastrojejunostomy)
K95.89	Other complications of other bariatric procedure (dilated gastrojejunostomy)
K21.0 - K21.9	Gastro-esophageal reflux disease
K83.8	Other specified diseases of biliary tract (Bile reflux) (listed as not covered for indications in CPB)

Mentioned devices/procedures without specific CPT/HCPCS in this sectionmixed

No codes listed

No explicit CPT/ICD codes in this sectionmixed

No codes listed

Key Definitions and Thresholds

Adult BMI threshold

Adult BMI threshold (general)BMI > 40 kg/m2 (or >37.5 kg/m2 for persons of Asian ancestry)

Adult BMI threshold with comorbidityBMI > 35 kg/m2 (or >32.5 kg/m2 for persons of Asian ancestry) plus at least one severe comorbidity (eg, clinically significant OSA, coronary heart disease, medically refractory hypertension, type 2 diabetes mellitus, or NASH)

Measurement timingBMI measured prior to preoperative preparatory program and documented in contemporaneous clinical records

Adolescent BMI threshold (post-growth)

Adolescent post-growth BMI thresholdBMI > 40 kg/m2 for adolescents who have completed bone growth

Skeletal maturity reference agesSkeletal maturity generally considered ~13 years for girls and ~15 years for boys

Program failure requirementAdolescents should have failed organized weight‑loss attempts (eg, ≥6 months) prior to consideration

Behavioral intervention sessions

Required program intensityIntensive multicomponent behavioral intervention must be documented and include nutrition, physical activity, and behavioral modification components

Minimum sessionsProgram must be intensive (12 or more sessions on separate dates) within 2 years prior to surgery

DocumentationProgram records may substitute for medical record documentation and must document participation and compliance

BMI — candidate thresholds

Primary BMI candidacyBMI ≥ 40 kg/m2

Alternate BMI candidacyBMI ≥ 35 kg/m2 with one or more significant comorbidities (eg, diabetes, coronary heart disease, obstructive sleep apnea)

Documentation requirementBMI should be measured and documented prior to preoperative preparatory program

Initial medical therapy weight loss goal

Initial medical therapy goalApproximate 10% reduction in body weight from baseline

Typical durationReasonable timeline ~6 months of medical therapy to achieve initial 10% weight loss

PurposeDemonstrates response to non‑surgical therapy and readiness for surgical intervention

Adolescent skeletal maturity / age thresholds

Routine adult age thresholdGenerally age 18 years or older for routine bariatric surgery

Adolescent skeletal maturityAdolescents considered only after skeletal maturity (approx. girls age 13, boys age 15) and completion of growth

Adolescent program requirementAdolescents should have failed organized weight‑loss attempts (eg, ≥6 months) and meet BMI severity criteria

ReShape trial BMI eligibility

ReShape trial BMI eligibilityAdults with BMI 30–40 kg/m2 (and at least one obesity‑related condition) in the ReShape Dual Balloon study

Age range in trialStudy included participants aged 22 to 60 years

Device duration contextDevice was temporary with removal at 6 months in the trial

GJ diameter for TORe

GJ (GJA) diameter threshold for TORe consideration> 2 cm (gastro‑jejunal anastomosis diameter >2 cm used in trials as an eligibility criterion)

Indication contextTypically applied for patients with weight regain or inadequate weight loss after RYGB with documented dilated GJA

DocumentationEndoscopic measurement of GJA diameter should be recorded in clinical documentation

VBLOC BMI eligibility (FDA labeling)

VBLOC (Maestro) FDA BMI labelingBMI ≥ 40–45 kg/m2, or BMI 35–39.9 kg/m2 with a related health condition and prior supervised weight‑management program within the past 5 years

Approval contextDevice FDA‑approved for specified BMI ranges but evidence for effectiveness is limited

Prior program requirementEligibility requires prior participation in a supervised weight‑management program per labeling

Follow-up duration reported

Reported follow‑up duration in cohortsFollow‑up reported up to 10 years in some cohorts/series

ContextLonger follow‑up durations appear in observational cohorts and registry reports for various procedures

ImplicationDurability and long‑term safety vary by procedure and evidence base; cite long‑term cohorts when available

Post-operative day 1 C-reactive protein (CRP)

POD1 CRP single‑center cut‑offPOD1 C‑reactive protein (CRP) ≥ 70 mg/L associated with early intra‑abdominal infection (sensitivity 81.2%, specificity 94.3%)

Pooled meta‑analysis cut‑offPooled POD1 CRP cut‑off ≈ 6.1 mg/dL (≈61 mg/L) reported in meta‑analysis for predicting early complications

Clinical useLow POD1 CRP (<70 mg/L or below pooled cut‑off) with reassuring signs may help rule out early IAI in enhanced recovery protocols

ESG 12-month weight loss

ESG 12‑month TBWLApproximately 16% total body weight loss at 12 months

ESG 12‑month EWLApproximately 60% excess weight loss at 12 months

Safety profilePooled adverse event rates reported ~1.5–2.3% in meta‑analyses

TORe outcomes

TORe %TWL outcomesPercent total weight loss (%TWL) at 3 / 6 / 12 months = 6.69% / 11.34% / 8.55% respectively (pooled meta‑analysis)

Technical successPooled technical success ~99.89% in meta‑analysis of studies

Pooled adverse eventsPooled AE rate ~11.4% (abdominal pain most common) in systematic review/meta‑analysis

Clinical Context and Evidence Summary

Bariatric surgery encompasses a range of operative and endoscopic procedures intended to produce sustained weight loss and improve obesity-related comorbidities. Common surgical approaches include Roux-en-Y gastric bypass (RYGB) — a combined restrictive and malabsorptive operation that creates a small gastric pouch and bypasses the proximal small bowel — and sleeve gastrectomy (SG), in which approximately 70–80% of the greater curvature is resected to reduce gastric volume. More extensive malabsorptive procedures include biliopancreatic diversion with or without duodenal switch (BPD/DS) and single-anastomosis variants such as SADI‑S/SIPS, which aim for greater weight and metabolic effects but require long‑term nutritional surveillance.

Restrictive procedures that rely primarily on reduced gastric capacity include laparoscopic adjustable silicone gastric banding (LASGB) and past techniques such as vertical banded gastroplasty (VBG); LASGB is adjustable but has been associated with high long‑term reoperation rates in some series, while VBG has largely fallen into disfavor. Other approaches and device-based therapies span a spectrum from established to investigational: temporary intragastric balloons and aspiration therapy (AspireAssist) provide non‑permanent, less‑invasive options; endoscopic full‑thickness suturing procedures (eg, transoral outlet reduction or endoscopic sleeve gastroplasty) are evolving as less‑invasive alternatives for selected patients; and gastrointestinal liners (EndoBarrier/DJBL), vagal nerve blocking (VBLOC/Maestro), and NOTES techniques remain investigational or have safety/ durability concerns in the literature.

Procedure selection balances expected efficacy, safety, technical complexity, and need for lifelong follow-up: RYGB and some malabsorptive procedures typically produce greater and more durable excess weight loss but carry higher risk of nutritional deficiencies and metabolic complications; restrictive options may have lower perioperative risk but more variable long‑term durability. Preoperative candidacy, perioperative care, and long‑term surveillance — including nutrition, micronutrient monitoring, and management of surgical complications — are integral to the overall approach to bariatric care.

Policy Revision History

2023study follow-upLatest

Brunaldi et al (2023) reported that in a 3-year follow-up after TORe most patients regained weight lost at 12 months, GJA diameter returned to baseline, and quality-of-life improvements were largely lost, concluding TORe effects are often not durable and procedures may be iterative.

(date not specified, study pooled review)evidence limitations noted

A pooled review found TORe studies were largely retrospective with short follow-up, heterogeneous pooled rates, loss to follow-up, and concerns about generalizability for inexperienced endoscopists, recommending longer-term studies and post-TORe endoscopic surveillance.

Policy Summary

PayerAetna

PolicyObesity Surgery

Policy CodePolicy 0157

Change TypeNo material clinical or coverage changes

Effective Date

Next Review Date

SourceLink

On This Page